The Zacks Medical-Drugs industry recovered from 2023 lows in early 2024 amid a slew of takeover deals. However, it slowed down thereafter, mostly due to macroeconomic pressure. Concerns around the economy and inflation, regular pipeline setbacks, uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s scrutiny of M&A deals are some of the headwinds faced by drug/biotech companies. However, the industry has shown signs of a comeback in May. M&A activity remains str ...